Anti-CD47 magrolimab and other anti-CD47 mAbs have recently been halted in the MDS and AML clinical trials; however, clinical development in solid tumors of magrolimab and other anti-CD47 mAbs continues and this will clarify whether the lack of efficacy of these antibodies was specific only to leukemia. This evidence concerns the gene CD47 and acute myeloid leukemia.